COVID-19 的疫苗和免疫疗法的最新进展。
Recent advances in vaccine and immunotherapy for COVID-19.
机构信息
Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare , Dhahran, Saudi Arabia.
Specialty Paediatric Medicine, Qatif Central Hospital , Qatif, Saudi Arabia.
出版信息
Hum Vaccin Immunother. 2020 Dec 1;16(12):3011-3022. doi: 10.1080/21645515.2020.1825896. Epub 2020 Nov 6.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of cases and hundreds of thousands of deaths. Beyond there being no available antiviral therapy, stimulating protective immunity by vaccines is the best option for managing future infections. Development of a vaccine for a novel virus is a challenging effort that may take several years to accomplish. This mini-review summarizes the immunopathological responses to SARS-CoV-2 infection and discusses advances in the development of vaccines and immunotherapeutics for COVID-19.
摘要
由 SARS-CoV-2 引起的 COVID-19 大流行导致了数百万人感染和数十万人死亡。除了没有可用的抗病毒疗法外，通过疫苗刺激保护性免疫是管理未来感染的最佳选择。开发针对新型病毒的疫苗是一项具有挑战性的工作，可能需要数年时间才能完成。这篇迷你综述总结了 SARS-CoV-2 感染的免疫病理反应，并讨论了 COVID-19 疫苗和免疫疗法的进展。
相似文献
1
Recent advances in vaccine and immunotherapy for COVID-19.
Hum Vaccin Immunother. 2020 Dec 1;16(12):3011-3022. doi: 10.1080/21645515.2020.1825896. Epub 2020 Nov 6.
2
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Front Immunol. 2021 Nov 18;12:748103. doi: 10.3389/fimmu.2021.748103. eCollection 2021.
3
Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets.
Cell Syst. 2021 Jan 20;12(1):102-107.e4. doi: 10.1016/j.cels.2020.11.010. Epub 2020 Nov 27.
4
Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.
Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.
5
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
Hum Vaccin Immunother. 2020 Dec 1;16(12):3055-3060. doi: 10.1080/21645515.2020.1796425. Epub 2020 Aug 26.
6
Repurposing CD8 T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
Oncoimmunology. 2020 Jul 16;9(1):1794424. doi: 10.1080/2162402X.2020.1794424.
7
Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
Hum Vaccin Immunother. 2020 Dec 1;16(12):3034-3042. doi: 10.1080/21645515.2020.1794685. Epub 2020 Aug 26.
8
Vaccine-induced protection in aging adults and pandemic response.
Biochem Biophys Res Commun. 2021 Jan 29;538:218-220. doi: 10.1016/j.bbrc.2020.10.090. Epub 2020 Nov 17.
9
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
10
Frontrunners in the race to develop a SARS-CoV-2 vaccine.
Can J Microbiol. 2021 Mar;67(3):189-212. doi: 10.1139/cjm-2020-0465. Epub 2020 Dec 2.
引用本文的文献
1
Countering the threatening surge in SARS-CoV-2 variants in China and its possible global implications: stocktaking in the ongoing FISU and the Asian Games vigilance.
Ann Med Surg (Lond). 2024 Feb 7;86(5):2373-2375. doi: 10.1097/MS9.0000000000001811. eCollection 2024 May.
2
End of the COVID-19 pandemic: Is it a reality?
Int J Surg Open. 2023 Jun 28:100644. doi: 10.1016/j.ijso.2023.100644.
3
Newer emerging SARS-COV2 variant: Omicron EG.5.
Ann Med Surg (Lond). 2023 Oct 4;85(12):5845-5846. doi: 10.1097/MS9.0000000000001386. eCollection 2023 Dec.
4
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.
Front Immunol. 2023 Sep 25;14:1264502. doi: 10.3389/fimmu.2023.1264502. eCollection 2023.
5
COVID-19 vaccines and their underbelly: Are we going the right way?
Health Sci Rep. 2023 Sep 3;6(9):e1540. doi: 10.1002/hsr2.1540. eCollection 2023 Sep.
6
Unravelling COVID-19 vaccination attributes worldwide: an extensive review regarding uptake, hesitancy, and future implication.
Ann Med Surg (Lond). 2023 Jun 12;85(7):3519-3530. doi: 10.1097/MS9.0000000000000921. eCollection 2023 Jul.
7
Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
Int J Surg Open. 2023 Jun;55:100625. doi: 10.1016/j.ijso.2023.100625. Epub 2023 May 18.
8
Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.
Vaccines (Basel). 2022 Oct 10;10(10):1689. doi: 10.3390/vaccines10101689.
9
Outer Membrane Vesicles: An Emerging Vaccine Platform.
Vaccines (Basel). 2022 Sep 21;10(10):1578. doi: 10.3390/vaccines10101578.
10
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.
Med Rev (2021). 2022 Apr 26;2(2):169-196. doi: 10.1515/mr-2021-0021. Epub 2022 May 25.
本文引用的文献
1
A human monoclonal antibody blocking SARS-CoV-2 infection.
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
2
A short review on antibody therapy for COVID-19.
New Microbes New Infect. 2020 Apr 20;35:100682. doi: 10.1016/j.nmni.2020.100682. eCollection 2020 May.
3
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
4
Molecular immune pathogenesis and diagnosis of COVID-19.
J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5.
5
The COVID-19 vaccine development landscape.
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
6
Developing Covid-19 Vaccines at Pandemic Speed.
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
7
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
8
Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.
Cell Mol Immunol. 2020 May;17(5):541-543. doi: 10.1038/s41423-020-0401-3. Epub 2020 Mar 17.
9
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
10
The convalescent sera option for containing COVID-19.
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
Zotero 插件